Annual report pursuant to Section 13 and 15(d)

Revenue (Tables)

v3.19.1
Revenue (Tables)
12 Months Ended
Dec. 31, 2018
Revenue from Contract with Customer [Abstract]  
Schedule of Revenues
During the years ended December 31, 2018 and 2017, respectively, the Company recognized revenues as follows (in thousands):
 
Years Ended December 31,
 
2018
 
2017
License fees
$
26,677

 
$
11,285

Research and development services
1,762

 
1,403

Milestone payments
571

 
12,573

Other revenues
91

 
14

Total Revenue
$
29,101

 
$
25,275


During the years ended December 31, 2018 and 2017, respectively, the Company recognized revenue from the following strategic partnerships and other license agreements (in thousands):
 
Years Ended December 31,
 
2018
 
2017
AstraZeneca
$
17,632

 
$
19,769

Seattle Genetics
5,413

 

Servier
4,508

 
1,907

Other
1,548

 
3,599

Total Revenue
$
29,101

 
$
25,275

Schedule of Potential Milestone Payments
Under the Company´s existing strategic partnerships and other license agreements, the Company could receive the following potential milestone payments (in millions):
 
Research, Development, Regulatory & Commercial Milestones
 
Sales Milestones
AstraZeneca
$
1,111

 
$
960

Servier
992

 
899

Seattle Genetics
769

 
450

Total potential milestone payments
$
2,872

 
$
2,309